Book[edited by] Bruce A. Chabner, Dan L. Longo.
Contents:
Clinical strategies for cancer treatment: the role of drugs
Target identification and drug discovery
Clinical drug development and marketing approval
Principles of pharmacokinetics
Delivering anticancer drugs to brain tumors
Pharmacogenetics
Physical barriers to drug delivery
Antifolates
5-fluoropyrimidines
Cytidine analogues
Purine antimetabolites
Hydroxyurea
Antimitotic drugs
Alkylating agents
Platinum analogues
Bleomycin and other antitumor antibiotics
Topoisomerase I-targeting drugs
Topoisomerase II inhibitors: anthracyclines
Topoisomerase II inhibitors: the epipodophyllotoxins
Asparaginase
Proteasome inhibitors
Histone deacetylase inhibitors in oncology
Differentiating agents
Arsenic trioxide
Antibodies
Inhibitors of tumor angiogenesis
Epidermal growth factor receptor inhibitors
HER2 inhibitors
Molecular targeted drugs
Signaling inhibitors: IGFR, PI3K pathway, embryonic signaling inhibitors, and mitotic kinase inhibitors
Cytokine therapy for cancer
Cancer vaccines
Adoptive cellular therapies
Thalidomide and its analogs in the treatment of hematologic malignancies, including multiple myeloma, and solid tumors
Hormonal therapy of breast cancer
Hormone therapy for prostate cancer
Drug therapy of pain in cancer patients
Hematopoietic growth factors
Antinausea medications
Bisphosphonates and other bone-targeted therapies
Intravenous access and catheter management
Late effects of cancer chemotherapy
Infertility after cancer chemotherapy.